Drug Name

Generic Name

Therapeutic
Class

Action

Antipsychotic Unclear.
agent
Thought
to
CLOZAPINE
interfere with
dopamine
Brand Name
binding
in
limbic system
Clozaril
of CNS, with
Denazapi
ne
high affinity for
Zaponex
dopamine4
receptors.
May
antagonize
adrenergic
,
cholinergic
,
histaminerg-ic
and
serotonergi-c
receptor.

Indication

Schizophreni
a in patients
unresponsive
to therapies.

Contraindicatio
n
Hypersensit
ivity to drug
Uncontrolle
d seizures
Severe
CNS
depression
or coma
Concurrent
use
of
drugs that
can cause
agranulocyt
osis
or
bone
marrow
depression.

Adverse Effect

Nursing Responsibility

CNS:
Sedation,
drowsiness,
dizziness,
headache, tremor,
insomnia, slurred
speech,
restlessness,
tardive dyskenisia,
akathisia, seizures.
CV:
Hypotension,
tachycardia, chest
pain. myocarditis.
EENT:
Blurred vision, dry
eyes,
nasal
congestion,
and
sinusitis.
GU:

Monitor WBC count

weekly for 6 months of
therapy, If its normal,
WBC testing can be
reduced to every other
week. Notify prescriber
immediately
if
WBC
counts decreases.
Monitor ECG and liver
function test.
If
drug
must
be
withdrawn
abruptly
monitor for patient for
psychosis and cholinergic
rebound.
Continue to monitor
WBC count weekly for 4
weeks,
after
therapy
ands.
Tell patient to allow

Urinary retention,
incontinence,
frequency, urgency
and
inhibited
ejaculation.
Musculoskeletal:
Muscle
spasm,
rigidity,back
and
muscle pain.
Hematlogic:
Agranulocytosis,
leucopenia,
hemolytic anemia,
neutropenia,
eosinphilia.
Respiratory:
Dyspnea,
respiratory arrest.
Skin:
Rash,
sweating,
Steven_johnson
Syndrome.
Other:

orally disintegrating tablet

to dissolve in mouth.
Advice
patient
to
immediately report new
onset of lethargy,
Weakness, fever, sore
throat, malaise, mucus
membrane ulcers, flulike
symptoms of infection.

Weigth
Fever.

gain,